ATE403867T1 - Evaluierung adjuvanshaltiger impfstoffe - Google Patents

Evaluierung adjuvanshaltiger impfstoffe

Info

Publication number
ATE403867T1
ATE403867T1 AT04739011T AT04739011T ATE403867T1 AT E403867 T1 ATE403867 T1 AT E403867T1 AT 04739011 T AT04739011 T AT 04739011T AT 04739011 T AT04739011 T AT 04739011T AT E403867 T1 ATE403867 T1 AT E403867T1
Authority
AT
Austria
Prior art keywords
antigen
solid phase
immunological activity
mixture
activity
Prior art date
Application number
AT04739011T
Other languages
English (en)
Inventor
Peter Wuertzen
Gitte Lund
Henrik Hugo Jacobi
Hans-Henrik Ipsen
Original Assignee
Alk Abello As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34276701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE403867(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alk Abello As filed Critical Alk Abello As
Application granted granted Critical
Publication of ATE403867T1 publication Critical patent/ATE403867T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04739011T 2003-08-05 2004-07-28 Evaluierung adjuvanshaltiger impfstoffe ATE403867T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49302003P 2003-08-05 2003-08-05
DKPA200301130 2003-08-05

Publications (1)

Publication Number Publication Date
ATE403867T1 true ATE403867T1 (de) 2008-08-15

Family

ID=34276701

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04739011T ATE403867T1 (de) 2003-08-05 2004-07-28 Evaluierung adjuvanshaltiger impfstoffe

Country Status (12)

Country Link
EP (1) EP1649287B1 (de)
KR (1) KR101132439B1 (de)
CN (1) CN1829917B (de)
AT (1) ATE403867T1 (de)
AU (1) AU2004269076B2 (de)
CA (1) CA2532726C (de)
DE (1) DE602004015611D1 (de)
DK (1) DK1649287T3 (de)
ES (1) ES2310732T3 (de)
MX (1) MXPA06001382A (de)
PL (1) PL1649287T3 (de)
WO (1) WO2005022157A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006014846D1 (de) 2005-09-15 2010-07-22 Alk Abello As Verfahren zur quantifizierung von allergenen
ES2349672T3 (es) * 2005-11-24 2011-01-10 Alk-Abello A/S Procedimiento para medir la actividad enzimática de enzima alergénica adsorbida.
PL1957661T3 (pl) 2005-11-24 2011-01-31 Alk Abello As Sposób mierzenia aktywności enzymatycznej zaadsorbowanego enzymu alergennego
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
ES2630029T3 (es) 2010-12-14 2017-08-17 Glaxosmithkline Biologicals Sa Análisis de citometría de flujo de materiales adsorbidos en sales metálicas
WO2013046226A2 (en) * 2011-08-04 2013-04-04 Serum Institute Of India Ltd. A novel quantification method for vaccines
CN109752560A (zh) * 2019-02-28 2019-05-14 艾棣维欣(苏州)生物制药有限公司 一种佐剂生物活性的检测方法
CN113009052A (zh) * 2021-02-22 2021-06-22 中国食品药品检定研究院 水痘减毒活疫苗中β-内酰胺类抗生素的检测方法
US20240371476A1 (en) * 2021-08-17 2024-11-07 Innovar Scientific, Inc. Vaccine Assessment and Compliance Testing Methods and Systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK140815B (da) * 1975-06-10 1979-11-19 Weeke Bengt Fremgangsmåde til påvisning eller bestemmelse af antistoffer i legemsvæsker ved hjælp af kendte antigener eller til bestemmelse af antigener ved hjælp af kendte antistoffer fra legemsvæsker samt et middel til anvendelse ved udøvelse af fremgangsmåden.
SU1746318A1 (ru) * 1990-06-05 1992-07-07 Институт полиомиелита и вирусных энцефалитов Способ определени концентрации белка Е вируса клещевого энцефалита в препаратах вакцины, сорбированных на гидроокиси алюмини
CN1276093C (zh) * 2001-05-15 2006-09-20 李卫云 一种检测丙肝病毒RdRp酶的方法，和载体以及用其转化的细胞株及应用

Also Published As

Publication number Publication date
PL1649287T3 (pl) 2009-04-30
ES2310732T3 (es) 2009-01-16
DE602004015611D1 (de) 2008-09-18
CA2532726C (en) 2013-03-12
AU2004269076A1 (en) 2005-03-10
CN1829917A (zh) 2006-09-06
MXPA06001382A (es) 2006-08-25
CA2532726A1 (en) 2005-03-10
DK1649287T3 (da) 2008-11-24
CN1829917B (zh) 2010-08-25
EP1649287A1 (de) 2006-04-26
EP1649287B1 (de) 2008-08-06
HK1094036A1 (en) 2007-03-16
KR20060126892A (ko) 2006-12-11
WO2005022157A1 (en) 2005-03-10
KR101132439B1 (ko) 2012-03-30
AU2004269076B2 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
FI960978A0 (fi) Anti-GP39-vasta-aineet ja niiden käyttö
CY1114047T1 (el) Νεοι φορεις εκφρασης και χρησεις αυτων
CY1110557T1 (el) Αντισωματα ιντερλευκινης-10
ATE494910T1 (de) Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
AR094125A2 (es) Anticuerpo aislado anti il-12
TR200103333T2 (tr) Dayanıklığı ve biyolojik uygunluğu iyileştiren yardımcı ilaç (SBA)
WO2006086561A3 (en) Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
DE60331677D1 (de) Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper
ATE403867T1 (de) Evaluierung adjuvanshaltiger impfstoffe
Colombani et al. Biomaterials and oxygen join forces to shape the immune response and boost COVID‐19 vaccines
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
PT1135158E (pt) Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica
DE50015629D1 (de) Verwendung cd28 spezifischer monoklonaler antikörpsetzung zur behandlung von virusinfektionen
DE60234015D1 (de) Latentes tuberkulose-diagnostisches antigen und verwendungsmethode
DE69738770D1 (de) Porphyromonas gingivalis Antigene zur Diagnose und Behandlung von Periodontitis
DK0749481T3 (da) Humaniserede monoklonale antistoffer mod human interleukin-4
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
Yu et al. Selection of SARS-coronavirus-specific B cell epitopes by phage peptide library screening and evaluation of the immunological effect of epitope-based peptides on mice
MX2007000916A (es) Anticuerpo enriquecido para detectar infeccion micobacteriana, metodos de uso y prueba de diagnostico que emplea la misma.
ATE291636T1 (de) Test-kit für tuberkulose-diagnose etc.
RU2006112203A (ru) Экспресс-тест для диагностирования болезни альцгеймера
Castric et al. Peptide epitope mapping in vaccine development: Introduction
Hejdeman et al. Better preserved immune responses after immunization with rgp 160 in HIV‐1 infected patients treated with highly active antiretroviral therapy than in untreated patients with similar CD4 levels during at 2 years' follow‐up

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1649287

Country of ref document: EP